When.com Web Search

  1. Ads

    related to: categories of diabetes medications

Search results

  1. Results From The WOW.Com Content Network
  2. Diabetes medication - Wikipedia

    en.wikipedia.org/wiki/Diabetes_medication

    Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin , most GLP-1 receptor agonists ( liraglutide , exenatide , and others), and pramlintide , all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.

  3. Category:Anti-diabetic drugs - Wikipedia

    en.wikipedia.org/wiki/Category:Anti-diabetic_drugs

    Combination diabetes drugs (19 P) D. Dipeptidyl peptidase-4 inhibitors (22 P) E. Experimental diabetes drugs (29 P) G. ... Pages in category "Anti-diabetic drugs"

  4. What Are GLP-1 Medications & Who Should Use Them? Here ... - AOL

    www.aol.com/glp-1-medications-them-heres...

    GLP-1 agonist medications have gained significant attention, especially for their role in weight management and type 2 diabetes treatment. While these medications have been around for nearly 20 ...

  5. Metformin - Wikipedia

    en.wikipedia.org/wiki/Metformin

    Anticholinergic drugs reduce gastric motility, prolonging the time drugs spend in the gastrointestinal tract. This impairment may lead to more metformin being absorbed than without the presence of an anticholinergic drug, thereby increasing the concentration of metformin in the plasma and increasing the risk for adverse effects.

  6. Are Diabetes Drugs Really Safe (& Reliable) for Weight Loss?

    www.aol.com/diabetes-drugs-really-safe-reliable...

    Several types of diabetes medications that may promote weight loss have weight loss as a side effect. These diabetes drugs for weight loss include: GLP-1s. What are GLP-1 medications? Glucagon ...

  7. SGLT2 inhibitor - Wikipedia

    en.wikipedia.org/wiki/SGLT2_inhibitor

    Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.